Trials / Unknown
UnknownNCT05266378
Pectoralis Nerve Block and Quality of Recovery in Mastectomy Patients
The Effect of Pectoralis Nerve Block on Quality of Recovery in Patients Undergoing Breast-conservative Surgery
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Effects of pectoralis nerve block on quality of recovery after breast surgery has been debated. We hypothesized there might exist relevant psychosocial factor or variable of pain sensitivity which would influence on the benefit of nerve block. This study aims to assess effect of pectoralis nerve block on QoR-15 score in subgroups stratified by such factors.
Detailed description
Study population All of patients will undergo partial mastectomy. 140 patients will be enrolled. Intervention Pectoralis nerve block will be performed in the Block group. Psychosocial factor screening Pain-detect, HADS, EQ-5D, PHQ-15 (somatic symptom), PCS (pain catastrophizing), BFI (big five inventory), HAM-A\&D, Pressure algometry (Pain sensitivity), Quantitative sensory test (pinprick) Study endpoints Quality of recovery (QoR)-15 Pain visual analogue scale Opioid consumption Breast Cancer Pain Questionnaire (BCPQ)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | PECs block | The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle. |
| OTHER | Not receiving PECs Block | In this group, the PECs block was not implemented. |
Timeline
- Start date
- 2022-02-23
- Primary completion
- 2024-02-23
- Completion
- 2025-03-24
- First posted
- 2022-03-04
- Last updated
- 2023-01-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05266378. Inclusion in this directory is not an endorsement.